Syngene International joins global industry consortium

Syngene International has joined a global consortium of 19 organisations from the healthcare industry, led by Bristol Myers Squibb, to help inform, improve and accelerate various aspects of COVID-19 testing, ranging from research to clinical diagnostic applications.

The consortium brings together a diverse group of companies with synergistic areas of expertise, including precision medicine, diagnostics, occupational health, pharmaceuticals and clinical testing laboratories, to help provide clarity and potential solutions to COVID-19 testing challenges.

Members will be able to share relevant expertise, materials and experiences to accelerate understanding of COVID-19. Members can also analyse available scientific and health data, materials and information to develop, improve and deploy current assays and new approaches for the COVID-19 testing paradigm.

The members can contribute knowledge gained from the collaborative research by publishing work that will inform the scientific community and general public of the consortium’s findings.

Mahesh Bhalgat, COO, Syngene, said, “Bristol Myers Squibb and Syngene have been research partners for 15 years. We fully support the aims of the consortium and look forward to sharing our experience and expertise from the last six months including conducting testing of our staff, producing proteins, antibodies and oligonucleotides for diagnostic kits, and operating one of the largest RT-PCR testing private laboratories in Karnataka. The world of medical science is benefitting enormously by sharing information about this coronavirus and we welcome the opportunity to contribute.”